Oncolytics Biotech Ebitda Over Time
| ONCY Stock | USD 0.94 0.01 1.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oncolytics Biotech Performance and Oncolytics Biotech Correlation. Oncolytics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Return On Assets (0.71) | Return On Equity (1.38) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Oncolytics Biotech and related stocks such as Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCPH | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (17.9 M) | (22.9 M) | (28 M) | (31.2 M) | (29.2 M) | (25 M) | (33.1 M) | (46.1 M) | (43.8 M) |
| MIST | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (23.8 M) | (57.8 M) | (50.7 M) | (43 M) | (59.6 M) | (56.8 M) | (59.7 M) |
| MCRB | (3 M) | (3 M) | (3 M) | (6 M) | (13.5 M) | (54.8 M) | (86.4 M) | (84.1 M) | (92.4 M) | (68.3 M) | (77.3 M) | (56.7 M) | (237.5 M) | (85.4 M) | (89.7 M) |
| DMAC | (597 K) | (4.4 M) | (7.7 M) | (6.3 M) | (4.8 M) | (1.4 M) | (2.3 M) | (4.3 M) | (5.5 M) | (10.7 M) | (12.2 M) | (13.6 M) | (14 M) | (19.3 M) | (18.3 M) |
| IKT | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (2.8 M) | (14.8 M) | (18.1 M) | (19.9 M) | (18.9 M) |
| XFOR | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (21.6 M) | (32.1 M) | (41.8 M) | (43.9 M) | (59.5 M) | (85.1 M) | (87.6 M) | (107.1 M) | (101.7 M) |
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (43.7 M) | (72.5 M) | (146.4 M) | (206.1 M) | (195.8 M) |
| HOOK | (11.7 M) | (11.7 M) | (11.7 M) | (11.7 M) | (11.7 M) | (11.7 M) | (11.7 M) | (11.7 M) | (14.8 M) | (49.6 M) | (49.1 M) | (77 M) | (69.6 M) | (77.3 M) | (81.2 M) |
| CVAC | (67.1 M) | (67.1 M) | (67.1 M) | (67.1 M) | (67.1 M) | (67.1 M) | (67.1 M) | (67.1 M) | (67.1 M) | (91.5 M) | (123.1 M) | (386.5 M) | (209.4 M) | (234.1 M) | (245.8 M) |
| KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.7 M) | (11.8 M) | (21.3 M) | (30.3 M) | (65.3 M) | (145.2 M) | 17.9 M | 18.8 M |
| VIR | (81.1 M) | (81.1 M) | (81.1 M) | (81.1 M) | (81.1 M) | (81.1 M) | (81.1 M) | (81.1 M) | (115.9 M) | (173.5 M) | 514.3 M | 420.8 M | 833.1 M | (684.3 M) | (650.1 M) |
Oncolytics Biotech and related stocks such as Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics Ebitda description
My Equities
My Current Equities and Potential Positions
| Oncolytics Biotech | ONCY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Alberta; Canada |
| Exchange | NASDAQ Exchange |
USD 0.94
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.